




PHARMACEUTICAL 2019

Aclaris Therapeutics Inc.
Rank 134 of 363





PHARMACEUTICAL 2019

Aclaris Therapeutics Inc.
Rank 134 of 363



The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 104% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	179,499
Cost of Goods Sold	6,850
Intangible Assets	91,455
Liabilities, Current	27,342
Liabilities, Non-Current	1,703
Other Assets	332
Other Compr. Net Income	177
Other Expenses	47,997
Other Liabilities	31,397
Other Net Income	2,676
Other Revenues	10,091
Property and Equipment	4,280
Research and Development	63,009
Selling, General and Administrative Expense	27,649

Output Variable	Value in 1000 USD
Assets	275,566
Liabilities	60,442
Expenses	145,505
Revenues	10,091
Stockholders Equity	215,124
Net Income	-132,738
Comprehensive Net Income	-132,650
Economic Capital Ratio	141%